INTRODUCTION
Descriptions of gout date from ancient times and its relation to uric acid and purine metabolism was established during the eighteenth and nineteenth centuries by the work of Scheele, Wollaston, Garrod and Emil Fischer. Gout then slipped into the doldrums.
By contrast, the second half of the present century has seen rapid developments including the realization that hyperuricaemia and gout have many causes. Biochemical, isotope, cell-culture and molecular techniques advanced our knowledge of purine metabolism, including the discovery of the first specific enzymatic defect responsible for one special type of gout. The examination of joint fluid for crystals has become a routine diagnostic procedure. Finally, from the therapeutic aspect, we have the facility to control the acute gout attack and the level of uric acid in the blood, thus transforming this painful and crippling scourge of centuries into the most easily treatable of the rheumatic diseases.
HYPERURICAEMIA
Despite the well-attested familial incidence of gout, the disorder does not follow any recognizable Mendelian pattern of inheritance; but writers of SO years ago often failed to appreciate the concept of polygenic inheritance:
The genetic peculiarities of hyperuricaemia arc ...quite satisfactorily explained if the gene involved is an autosomal dominant which lacks penetrance in both sexes, but has a much lower penetrance in the female than in the male l .
It came to be realized, however, that while a few patients with gout possess a single genetic abnormality, the majority derive their hyperuricaemia from a number of contributory factors, namely quantitative variations in genetically determined metabolic and renal functions, the precise nature of which has yet to be elucidated, to which are added in many instances the effects of external agents. The familial nature of gout is no doubt due to a combination of genetic and environmental influences. During the middle years of this century a heated debate took place concerning the relative importance of 'overproduction' and 'under-excretion' of uric acid in the genesis of hyperuricaemia. The problem remains unresolved but a number of studies have shown that renal clearance of urate is lower in most gout patients than in healthy controls; abnormalities in renal tubular function appear to be a major factor.
The discovery in 1967 2 of X-linked deficiency of the purine salvage enzyme hypoxanthine guanine phosphoribosyl transferase as the cause of the Lesch-Nyhan syndromecharacterized by mental retardation, compulsive aggression, involuntary movements and gross over-production of uric acid with gout and renal calculi-was an advance of major importance in our concept of hyperuricaemia. The condition is rare, as is that of partial deficiency in which the neurological features may be minimal or absent, and as also are the few other specific enzyme abnormalities which can cause over-production of uric acid.
The same period saw the identification or clarification of various environmental factors predisposing to hyperuricaemia and gout, particularly food (with regard to both its purine and its calorie content), alcoholic liquors and drugs, especially diuretics, together with other important but less common influences such as ketosis and lead poisoning.
The concept of primary and secondary gout was developed to distinguish hyperuricaemia attributable to an inherent metabolic or renal abnormality from that where an identifiable (and usually acquired) cause can be demonstrated. These terms continue to serve a useful clinical and descriptive purpose but again the distinction is not always clear-cut. For example, in polycythaemia rubra vera (a classical cause of secondary gout) high urate levels and gouty arthritis tend to be associated with renal failure rather than with the extent of thrombocythaemia, megakaryocyte proliferation or mvelofihrosis'. Similarly, diuretic-induced gout occurs in patients in whom there is an additional cause of hyperuricaemia, usually impaired renal function".
CRYSTAL-INDUCED INFLAMMATION
The forms of crystal deposition disease best known to the ancients were stone in the urinary tract and gout. Bladder calculi and tophi have been recovered from Egyptian mummies 7000 years old. Hippocrates was familiar with both conditions. His refusal to cut for the stone, 'leaving such procedures to the practitioners of the craft', is well known, as are his observations about the rarity of gout in pre-menopausal women and eunuchs. Of course, descriptions of crystals had to await the advent of the microscope. This came with the Dutchman Antoni van Leeuwenhoek (1632-1723), who collected chalky material from a gouty friend's heel and became the first person to demonstrate the needle-shaped crystals of sodium urate under the microscopes. Sir Alfred Garrod'' considered that 'the deposited urate of soda may be looked upon as the cause, and not the effect, of the gouty inflammation'. He did not demonstrate crystals in joints, although he did describe his famous 'thread test', whereby hyperuricaemic serum from a gouty subject can be shown to deposit a precipitate of solid urate upon a piece of thread immersed in it.
At the turn of the last century there were observations of urate crystals being phagocytosed by leucocytes within cutaneous tophi and of acute inflammation following subcutaneous injection into animals and man, with the evolution of granulomatous lesions/. But the idea of crystalinduced inflammation did not gain general acceptance. The finding of urate crystals in synovial fluid from gout patients was thought to be infrequent and of little diagnostic value. One also has to remember that, before the days of the autoclave, sterilization was less efficient than it is today; needling of joints was regarded by many as a dangerous procedure.
The classical paper, in 1961, of McCarty and Hollanders described how the visualization of urate crystals in synovial fluid was in fact a measure of great diagnostic assistance. They could be seen with plain light microscopy but were much more easily recognized under polarized light, permitting the ready distinction of gout from calcium pyrophosphate arthropathy, the other major form of crystal synovitis", It has even been suggested that a diagnosis of gouty arthritis cannot be sustained without the demonstration of urate crystals in synovial fluid but this may be a counsel of perfection.
Crystals almost certainly do play an essential role in inducing joint inflammation (rather than being just 'innocent bystanders'), since injection of crystalline particles of the right size and shape-not only urate but also oxalate and other substances-has been shown to produce an inflammatory response in skin, subcutaneous tissue and joints in man and animals10,11. Factors leading to crystal deposition (e.g. supersaturation with urate; temperature; trauma) and to the subsequent inflammatory response (e.g. crystal size, shape, surface properties and protein coating; polymorph phagocytosis; the action of inflammatory mediators) remain incompletely understood 1 2, 13. Many questions are unanswered. Why do not all hyperuricaemic persons deposit urate in their tissues? Why is deposition focal, occurring commonly in some tissues, such as cartilage, synovial membrane and subcutaneous tissue, and not in others, such as muscle? And, most intriguingly, why is the attack of gout self-limiting? Urate can certainly be seen arthroscopically deposited in joints which are clinically normall". Why are these little crystals at some times bland, dormant and innocuous and at others capable of producing one of the most intense forms of pain known to man?
TREATMENT OF GOUT
As has been well pointed out by the late Gerald Rodnan IS, gouty arthritis and attendant tophaceous disease respond so well to treatment nowadays that it is difficult for the young physician to appreciate the dread once inspired by this disorder.
Up to the modern era, colchicine was the only agent capable of dealing effectively with acute gouty arthritis and indeed it still has a part to play, particularly when nonsteroidal anti-inflammatory drugs are contraindicated. But its side-effects--diarrhoea and vomiting with a high toxic/ therapeutic ratio-make it a difficult drug to handle. Phenylbutazone, a pyrazole derivative first synthesized in 1946 and introduced clinically in 1951 (having previously been used as a solvent for aminopyrine), became established as being highly effective in the suppression of acute gouty arthritis, as well as being useful in other inflammatory conditions. Its withdrawal in the UK because of bonemarrow toxicity (except for hospital-treated patients with ankylosing spondylitis) remains contentious. An estimated marrow-related mortality of one per 250000 patientmonths'f indicates that toxicity with short-term treatment for acute gout must be extremely rare; and there are occasional patients who much prefer phenylbutazone to other more recently introduced non-steroidal anti-inflammatory drugs such as indomethacin. Clinical trials, however, have indicated that overall there is little to choose between them.
The most remarkable development over the past 50 years has been our ability to control the plasma level of uric acid with complete remission of symptoms. This was possible previously to some extent. The uricosuric action of salicylate has been known for over 100 years and it is perfectly feasible to control the uric acid level with prolonged medication 1 7. However, dosage has to be high (4.0 g to 9.0 g daily), smaller amounts producing the paradoxical urate-retaining effect 1S • Such a sustained high dose is unacceptable for most people. Salicylate also antagonizes the action of other uricosuric drugs such as probenecid. Cinchopen (phenylquinolin carbonic acid) was introduced as a urate-lowering drug in 1908; it became widely prescribed for the treatment of gout, but fell out of favour because of hepatotoxicity.
Caronamide and probenecid are agents that selectively and reversibly inhibit the transport mechanisms responsible for the renal tubular secretion of the penicillins, paminohippurate, p-aminosalicylic acid and phenol red. Caronamide, which had been introduced to delay the excretion of penicillin, was found to increase the renal clearance of uric acid by Wolfson et al. 19 , who introduced the term 'uricosuric effect'. Probenecid was shown to be effective in smaller dosage and to lack the side-effects of caronamide (with the exception of attacks of acute gout soon after commencing treatment, a phenomenon now well known to occur whenever the serum uric acid is lowered rapidly, by any method).
Phenylbutazone is uricosuric, but only weakly so. Of various analogues tested, sulphinpyrazone was found to have uricosuric properties comparable to those of probenecid and both of these drugs are in use today. In continental Europe the very powerful uricosuric drug benzbromarone is also available, but we do not have it for routine use in the UK.
Management of hyperuricaemia by uricosuric drugs is by no means always satisfactory. Proper control of uric acid levels is sometimes difficult and increased excretion of uric acid by way of the kidney leads to a greater risk of urolithiasis. Moreover, uricosuric agents depend for their action upon functioning nephrons and they lose their effect in the presence of renal failure.
The introduction of uricosuric drugs had thus in a way been accidental-a by-product, as it were, of attempts to maintain blood levels of penicillin-and it is remarkable that allopurinol likewise was not primarily intended to be used in the treatment of gout and hyperuricaemia. It was first synthesized for trial as a chemotherapeutic agent but by itself had little or no effect on experimental tumours. As an inhibitor of the enzyme xanthine oxidase it was used in the treatment of leukaemia to suppress the oxidation of 6-mercaptopurine to its inert metabolite 6-thiouric acid. Xanthine nxidase also mediates the oxidation of xanthine and hypoxanthine to uric acid and patients given allopurinol were found-not unexpectedly-to show a pronounced reduction in levels of both plasma and urinary uric acid/". For the past 30 years the drug has remained established as the standard-and extremely satisfactoryform of maintenance therapy in gout and uric acid stones.
The introduction of gene targeting technology is having a considerable impact upon our knowledge of purine metabolism. For example, the urate oxidase (uricase) gene has been disrupted in the mouse by homologous recombination in embryonic stem cells:". Unlike the situation in humans and some other primates (who have lost the enzyme urate oxidase in the course of evolution), deficiency in these mice was found to lead to rapid hyperuricaemia, urate nephropathy and death. The implications of such dramatic investigations for the study and treatment of human gout are as yet unclear. In view of the ease with which most patients with gout can be effectively treated it seems unlikely that there will be a general need for molecular therapeutic methods. However, novel antihyperuricaemic agents may come to have a place in special situations, such as the recently reported successful injection of urate oxidase to treat severe polyarticular and tophaceous cyclosporine-associated gout in heart transplant recipients, in whom allopurinol (with azathioprine) caused leucopenia and uricosuric drugs were ineffective or contraindicated'<.
